Fast-acting Analgesics Market to Reach an Estimated $2.5 Billion by 2016.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49698) has announced the addition of Datamonitor's new report: Pipeline Insight: Breakthrough Pain - Fast-Acting Players will Capture Majority Market Share to their offering. In spite of generic Actiq competition, Cephalon's reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics Analgesics Definition Analgesics are medicines that relieve pain. Purpose Analgesics are those drugs that mainly provide pain relief. will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016. Scope of this title: * Discussion and quantification of the patient potential and market size of breakthrough pain in both malignant and non-malignant diseases * Assessment of the unmet clinical needs in breakthrough pain as validated by interviewed international opinion leaders * Detailed overview and assessment of key drugs in Phase II and above clinical development, including Fentora, Rapinyl, and BEMA Fentanyl fentanyl /fen·ta·nyl/ (fen´tah-nil) an opioid analgesic; the citrate salt is used as an adjunct to anesthesia, in the induction and maintenance of anesthesia, in combination with droperidol (or similar agent) as a neuroleptanalgesic, and * Ten-year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. to 2016 for key pipeline products Highlights of this title: Relatively high unmet clinical need, additional patient groups, the launch of new products, and no further key patent expiries within the next ten years will see the breakthrough pain market more than double from 2005 to reach $2.5 billion in 2016. As well as for oral transmucosal fentanyl products, opportunities also exist for non-oral analgesics. Intranasal in·tra·na·sal adj. Within the nose. and inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. technology may provide convenient and fast acting analgesia analgesia /an·al·ge·sia/ (an?al-je´ze-ah) 1. absence of sensibility to pain. 2. the relief of pain without loss of consciousness. and are potentially suitable for self-administration in the lucrative outpatient setting. A key growth strategy will be to gain initial approval for cancer breakthrough pain and then drive sales in additional indications through off-label use Off-label use A drug that is prescribed for uses, periods of time, or at dosages that are not FDA-approved. Mentioned in: Antidepressant Drugs, SSRI off-label use or regulatory approval. Key non-malignant applications for fast acting analgesics include breakthrough pain in post-operative pain, chronic low back, and osteoarthritic pain. Reasons to order your copy: * Explore the strategies that have made Cephalon Ceph´a`lon n. 1. (Zool.) The head. the market leading company in breakthrough pain * Examine the potential for intranasal and inhaled analgesics and what other factors companies are using to differentiate their products * Analyze the competitive environment at the time of product launch and identify lucrative gaps in the market For more information visit http://www.researchandmarkets.com/reports/c49698 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion